Lineage Cell Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
Lineage Cell Therapeutics, Inc. (LCTX) reported Gain (Loss) on Extinguishment of Debt of $523.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-03-09
- Lineage Cell Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $523.00K.
- Lineage Cell Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2017-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was $523.00K.
- Lineage Cell Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2017 was -$2.80M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $523.00K derived: sum of 3 quarters · filed 2023-03-09 | $523.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $523.00K derived: sum of 2 quarters · filed 2022-11-10 | $523.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $523.00K 10-Q · filed 2022-08-11 | $523.00K 10-Q · filed 2022-08-11 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$2.80M derived: sum of 2 quarters · filed 2019-03-14 | -$2.80M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$2.80M 10-Q · filed 2018-11-08 | -$2.80M 10-Q · filed 2018-11-08 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |